Tuesday, December 31, 2019
11:01 AM EST – Neovasc Inc. : Today announced the submission of a Premarket Approval application to the U.S. Food and Drug Administration for its Neovasc Reducer™ medical device for the treatment of refractory angina. The submission also includes a request for an Advisory Panel meeting. Neovasc Inc. (T.NVCN) shares were up $3.13 at 8.22.
Stocks in Play: Neovasc Inc., Tue, 31 Dec 2019 11:12:58 EST